These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1322559)

  • 1. Effect of piperacillin/tazobactam therapy on intestinal microflora.
    Nord CE; Brismar B; Kasholm-Tengve B; Tunevall G
    Scand J Infect Dis; 1992; 24(2):209-13. PubMed ID: 1322559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of piperacillin/tazobactam treatment on human bowel microflora.
    Nord CE; Brismar B; Kasholm-Tengve B; Tunevall G
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():61-5. PubMed ID: 8383656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
    Nord CE
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S35-8. PubMed ID: 7962987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections.
    Mouton Y; Leroy O; Beuscart C; Chidiac C; Senneville E; Ajana F; Lecocq P
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():87-95. PubMed ID: 8383658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ticarcillin/clavulanate on the intestinal microflora.
    Nord CE; Bergan T; Thorsteinsson SB
    J Antimicrob Chemother; 1989 Nov; 24 Suppl B():221-6. PubMed ID: 2606816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Bryson HM; Brogden RN
    Drugs; 1994 Mar; 47(3):506-35. PubMed ID: 7514977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
    Appelbaum PC
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin/tazobactam in the treatment of polymicrobial infections.
    Gorbach SL
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S27-34. PubMed ID: 7962986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of soft tissue infections with piperacillin/tazobactam.
    Tassler H; Cullmann W; Elhardt D
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():105-12. PubMed ID: 8383651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.
    Verbist L; Verhaegen J; Wouters C; Vandenhoven G
    J Antimicrob Chemother; 1996 Feb; 37(2):285-93. PubMed ID: 8707738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam in complicated urinary tract infections.
    Nowé P
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S39-42. PubMed ID: 7962988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal concentrations of piperacillin and tazobactam in elderly patients.
    Wilcox MH; Brown A; Freeman J
    J Antimicrob Chemother; 2001 Jul; 48(1):155-6. PubMed ID: 11418534
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
    Vestweber KH; Grundel E
    Eur J Surg Suppl; 1994; (573):57-60. PubMed ID: 7524797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
    Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
    Perry CM; Markham A
    Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of piperacillin/tazobactam in phase I and III clinical studies.
    Kuye O; Teal J; DeVries VG; Morrow CA; Tally FP
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():113-24. PubMed ID: 8383652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.